MedTechAI is the financing arm of Oxford Immune Algorithmics (OIA)
MedTechAI owns 28% of OIA. Financing to acquire another 10% equals ownership of 38% of OIA • OIA, the creators of Algocyte, have scholarly roots at top global research institutions. • Originated at Karolinska*, incubated by the University Oxford, and co-developed with the University of Cambridge • MedTechAI owns 70% of Algocyte Canada
OIA/Algocyte: Transforming the “medicine of what” to the “medicine of why” Purpose (Why does OIA exist?) Combining AI and Technology to provide precise, predictive and personalized valued – based medicine, focused on causal diagnostics.